SPRAY FORMULATION BASED ON IMMUNOGLOBIN Y ANTIBODIES HAVING TREATMENT AND PROTECTION CHARACTERISTICS FOR ALL STRAINS OF INFLUENZA A VIRUS

The present invention relates to obtaining nano-biotechnologic agent (lgY@PLGA) as a result of encapsulating with poly (lactic-co-glycolic-acid) (PLGA) which is a polymer which does not show toxic effect in the metabolism, in order to prevent specific immuno-globulin Y antibodies from fragmenting be...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	UNAL, Gokce, BUDAMA KILINC, Yasemin
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to obtaining nano-biotechnologic agent (lgY@PLGA) as a result of encapsulating with poly (lactic-co-glycolic-acid) (PLGA) which is a polymer which does not show toxic effect in the metabolism, in order to prevent specific immuno-globulin Y antibodies from fragmenting before reaching their targets in the body and in order to provide specific immuno-globulin Y antibodies to bind to the external region (M2e) of the M2 protein of the influenza A virus which is substantially well-protected and in order to provide deactivation of the viruses, and relates to application of said nano-biotechnologic agent (lgY@PLGA) in spray form. La présente invention concerne l'obtention d'un agent nano-biotechnologique (lgY@PLGA) suite à l'encapsulation avec du poly (acide lactique-co-glycolique) (PLGA) qui est un polymère qui ne présente pas d'effet toxique dans le métabolisme, afin d'empêcher des anticorps immunoglobuline Y spécifiques de se fragmenter avant d'atteindre leurs cibles dans le corps et afin de fournir des anticorps immunoglobuline Y spécifiques à se lier à la région externe (M2e) de la protéine M2 du virus de la grippe A qui est sensiblement bien protégé et afin d'assurer la désactivation des virus, et concerne l'application dudit agent nano-biotechnologique (lgY@PLGA) sous forme de spray.